COVID-19 and Antimicrobial Resistance: A Review

As the world continues to respond to the coronavirus pandemic (COVID-19), there is a larger hidden threat of antimicrobial resistance (AMR) lurking behind. AMR remains worrisome in that the pathogens causing resistant infections to thrive in hospitals and medical facilities, putting all patients at...

Full description

Bibliographic Details
Main Authors: Yusuff Adebayo Adebisi, Aishat Jumoke Alaran, Melody Okereke, Gabriel Ilerioluwa Oke, Oladunni Abimbola Amos, Omotayo Carolyn Olaoye, Iyiola Oladunjoye, Azeez Yusuff Olanrewaju, Nelson Ashinedu Ukor, Don Eliseo Lucero-Prisno
Format: Article
Language:English
Published: SAGE Publishing 2021-07-01
Series:Infectious Diseases
Online Access:https://doi.org/10.1177/11786337211033870
id doaj-f864ef81b6544e1889f433084a85c503
record_format Article
spelling doaj-f864ef81b6544e1889f433084a85c5032021-07-31T21:33:30ZengSAGE PublishingInfectious Diseases1178-63372021-07-011410.1177/11786337211033870COVID-19 and Antimicrobial Resistance: A ReviewYusuff Adebayo Adebisi0Aishat Jumoke Alaran1Melody Okereke2Gabriel Ilerioluwa Oke3Oladunni Abimbola Amos4Omotayo Carolyn Olaoye5Iyiola Oladunjoye6Azeez Yusuff Olanrewaju7Nelson Ashinedu Ukor8Don Eliseo Lucero-Prisno9Faculty of Pharmacy, University of Ibadan, Ibadan, NigeriaNational Institute for Pharmaceutical Research and Development, Abuja, NigeriaFaculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Kwara State, NigeriaDepartment of Medical Laboratory Science, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, NigeriaFaculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, NigeriaFaculty of Pharmacy, Obafemi Awolowo University Ile-Ife, Jos, NigeriaDepartment of Microbiology, University of Ilorin, Ilorin, Kwara State, NigeriaFaculty of Pharmacy, University of Ibadan, Ibadan, NigeriaFaculty of Pharmaceutical Sciences, University of Uyo, Uyo, NigeriaDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UKAs the world continues to respond to the coronavirus pandemic (COVID-19), there is a larger hidden threat of antimicrobial resistance (AMR) lurking behind. AMR remains worrisome in that the pathogens causing resistant infections to thrive in hospitals and medical facilities, putting all patients at risk, irrespective of the severity of their medical conditions, further compounding the management of COVID-19. This study aims to provide overview of early findings on COVID-19 and AMR as well as to provide recommendations and lesson learned toward improving antimicrobial stewardship. We conducted a rapid narrative review of published articles by searching PubMed and Google Scholar on COVID-19 and Antimicrobial Resistance with predetermined keywords. Secondary bacterial infections play crucial roles in mortality and morbidity associated with COVID-19. Research has shown that a minority of COVID-19 patients need antibiotics to treat secondary bacterial infections. Current evidence reiterates the need not to give antibiotic therapy or prophylaxis to patients with mild COVID-19 or to patients with suspected or confirmed moderate COVID-19 illness unless it is indicated. The pandemic has also brought to the fore the deficiencies in health systems around the world. This comes with a lot of lessons, one of which is that despite the advances in medicine; we remain incredibly vulnerable to infections with limited or no standard therapies. This is worth thinking in the context of AMR, as the resistant pathogens are evolving and leading us to the era of untreatable infections. There is a necessity for continuous research into understanding and controlling infectious agents, as well as the development of newer functional antimicrobials and the need to strengthen the antimicrobial stewardship programs.https://doi.org/10.1177/11786337211033870
collection DOAJ
language English
format Article
sources DOAJ
author Yusuff Adebayo Adebisi
Aishat Jumoke Alaran
Melody Okereke
Gabriel Ilerioluwa Oke
Oladunni Abimbola Amos
Omotayo Carolyn Olaoye
Iyiola Oladunjoye
Azeez Yusuff Olanrewaju
Nelson Ashinedu Ukor
Don Eliseo Lucero-Prisno
spellingShingle Yusuff Adebayo Adebisi
Aishat Jumoke Alaran
Melody Okereke
Gabriel Ilerioluwa Oke
Oladunni Abimbola Amos
Omotayo Carolyn Olaoye
Iyiola Oladunjoye
Azeez Yusuff Olanrewaju
Nelson Ashinedu Ukor
Don Eliseo Lucero-Prisno
COVID-19 and Antimicrobial Resistance: A Review
Infectious Diseases
author_facet Yusuff Adebayo Adebisi
Aishat Jumoke Alaran
Melody Okereke
Gabriel Ilerioluwa Oke
Oladunni Abimbola Amos
Omotayo Carolyn Olaoye
Iyiola Oladunjoye
Azeez Yusuff Olanrewaju
Nelson Ashinedu Ukor
Don Eliseo Lucero-Prisno
author_sort Yusuff Adebayo Adebisi
title COVID-19 and Antimicrobial Resistance: A Review
title_short COVID-19 and Antimicrobial Resistance: A Review
title_full COVID-19 and Antimicrobial Resistance: A Review
title_fullStr COVID-19 and Antimicrobial Resistance: A Review
title_full_unstemmed COVID-19 and Antimicrobial Resistance: A Review
title_sort covid-19 and antimicrobial resistance: a review
publisher SAGE Publishing
series Infectious Diseases
issn 1178-6337
publishDate 2021-07-01
description As the world continues to respond to the coronavirus pandemic (COVID-19), there is a larger hidden threat of antimicrobial resistance (AMR) lurking behind. AMR remains worrisome in that the pathogens causing resistant infections to thrive in hospitals and medical facilities, putting all patients at risk, irrespective of the severity of their medical conditions, further compounding the management of COVID-19. This study aims to provide overview of early findings on COVID-19 and AMR as well as to provide recommendations and lesson learned toward improving antimicrobial stewardship. We conducted a rapid narrative review of published articles by searching PubMed and Google Scholar on COVID-19 and Antimicrobial Resistance with predetermined keywords. Secondary bacterial infections play crucial roles in mortality and morbidity associated with COVID-19. Research has shown that a minority of COVID-19 patients need antibiotics to treat secondary bacterial infections. Current evidence reiterates the need not to give antibiotic therapy or prophylaxis to patients with mild COVID-19 or to patients with suspected or confirmed moderate COVID-19 illness unless it is indicated. The pandemic has also brought to the fore the deficiencies in health systems around the world. This comes with a lot of lessons, one of which is that despite the advances in medicine; we remain incredibly vulnerable to infections with limited or no standard therapies. This is worth thinking in the context of AMR, as the resistant pathogens are evolving and leading us to the era of untreatable infections. There is a necessity for continuous research into understanding and controlling infectious agents, as well as the development of newer functional antimicrobials and the need to strengthen the antimicrobial stewardship programs.
url https://doi.org/10.1177/11786337211033870
work_keys_str_mv AT yusuffadebayoadebisi covid19andantimicrobialresistanceareview
AT aishatjumokealaran covid19andantimicrobialresistanceareview
AT melodyokereke covid19andantimicrobialresistanceareview
AT gabrielilerioluwaoke covid19andantimicrobialresistanceareview
AT oladunniabimbolaamos covid19andantimicrobialresistanceareview
AT omotayocarolynolaoye covid19andantimicrobialresistanceareview
AT iyiolaoladunjoye covid19andantimicrobialresistanceareview
AT azeezyusuffolanrewaju covid19andantimicrobialresistanceareview
AT nelsonashineduukor covid19andantimicrobialresistanceareview
AT doneliseoluceroprisno covid19andantimicrobialresistanceareview
_version_ 1721246541685981184